The Cost of Stopping (Futility) Rules Telaprevir and Boceprevir in the Treatment of Genotype 1 Hepatitis C Patients in Brazil

被引：0
|
作者：
Morais, A. D. [1 ]
Pereira, M. L. [1 ]
机构：
[1] Janssen Cilag Farmaceut, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.137
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A345 / A345
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Enea, Marco
    Bruno, Raffaele
    Bronte, Fabrizio
    Capursi, Vincenza
    Cicchetti, Americo
    Colombo, Giorgio L.
    Di Marco, Vito
    Gasbarrini, Antonio
    Craxi, Antonio
    HEPATOLOGY, 2012, 56 (03) : 850 - 860
  • [2] COST PER CURE OF TELAPREVIR AND BOCEPREVIR IN TREATMENT-NAIVE GENOTYPE 1 HEPATITIS C PATIENTS WITH F2 FIBROSIS IN BRAZIL
    Morais, A. D.
    Pereira, M. L.
    VALUE IN HEALTH, 2013, 16 (07) : A352 - A352
  • [3] The Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1
    Kieran, Jennifer
    Schmitz, Susanne
    O'Leary, Aisling
    Walsh, Cathal
    Bergin, Colm
    Norris, Suzanne
    Barry, Michael
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (02) : 228 - 235
  • [4] Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Cabibbo, Giuseppe
    Ruggeri, Matteo
    Enea, Marco
    Bruno, Raffaele
    Capursi, Vincenza
    Gasbarrini, Antonio
    Alberti, Alfredo
    Craxi, Antonio
    JOURNAL OF HEPATOLOGY, 2013, 59 (04) : 658 - 666
  • [5] Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
    Jacobson, Ira M.
    Marcellin, Patrick
    Zeuzem, Stefan
    Sulkowski, Mark S.
    Esteban, Rafael
    Poordad, Fred
    Bruno, Savino
    Burroughs, Margaret H.
    Pedicone, Lisa D.
    Boparai, Navdeep
    Deng, Weiping
    DiNubile, Mark J.
    Gottesdiener, Keith M.
    Brass, Clifford A.
    Albrecht, Janice K.
    Bronowicki, Jean-Pierre
    HEPATOLOGY, 2012, 56 (02) : 567 - 575
  • [6] COST PER SUSTAINED VIROLOGICAL RESPONSE OF TELAPREVIR AND BOCEPREVIR IN THE TREATMENT OF GENOTYPE 1 HEPATITIS C PATIENTS ACCORDING TO THE PREVIOUS TREATMENT RESPONSE AND THE METAVIR GROUPS IN BRAZIL
    Morais, A. D.
    Pereira, M. L.
    VALUE IN HEALTH, 2012, 15 (07) : A395 - A395
  • [7] Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection
    Adda, Nathalie
    Bartels, Doug J.
    Gritz, Linda
    Kieffer, Tara L.
    Tomaka, Frank
    Bengtsson, Leif
    Luo, Don
    Jacobson, Ira M.
    Kauffman, Robert S.
    Picchio, Gaston
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (02) : 193 - 195
  • [8] Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir
    Moradpour, Darius
    Muellhaupt, Beat
    SWISS MEDICAL WEEKLY, 2012, 142
  • [9] Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
    Gomes, Lenyta Oliveira
    Teixeira, Marina Rodrigues
    da Rosa, Junior Andre
    Feltrin, Alberi Adolfo
    Rodrigues, Joao Paulo, V
    Vecchi, Mariane D'avila
    Carneiro, Jane Meire M.
    Noblat, Lucia de Aratijo C. B.
    Chacha, Silvana Gama F.
    Martinelli, Ana de Lourdes C.
    Pereira, Leonardo Regis L.
    Silveira, Marysabel Pinto T.
    Blatt, Carine Raquel
    Farias, Mareni Rocha
    REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2018, 60
  • [10] EFFICACY AND SAFETY OF TELAPREVIR AND BOCEPREVIR IN PATIENTS WITH HEPATITIS C GENOTYPE 1: A META-ANALYSIS
    Park, C.
    Jiang, S.
    Lawson, K. A.
    VALUE IN HEALTH, 2013, 16 (03) : A80 - A80
12345